A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose of TAK-792 in the Healthy Japanese and Adult
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2016
At a glance
- Drugs SCO-792 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Takeda
- 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Nov 2015 Protocol has been amended in treatment table in change of TAK-792 dose from 900 mg to 1250 mg.